# New Orleans BioFund

> New Orleans BioFund is a VC fund backing Health Care and Biotechnology. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New Orleans, United States
- Total investments: 22
- Last investment: Apr 2026
- Lead investor: 5%
- Last fund: Jun 2017
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/new-orleans-biofund/
- X (Twitter): https://twitter.com/NOLABioFund
- Website: https://neworleansbio.com/biofund/
- Facebook: https://www.facebook.com/NOLABioFund/

New Orleans BioFund is a VC fund in New Orleans focused on Health Care and Biotechnology. New Orleans BioFund was created to help regional startup companies grow, create jobs, and contribute to the economic revitalization of New Orleans. Capital is often difficult to obtain for small businesses and startups, which are high-risk ventures. The innovative BioFund program supports small businesses that may not qualify for traditionalfinancing options. These investments help bridge a critical funding gap, thus allowing companies to better position themselves for growth and success.The New Orleans BioFund operates in all industries, but places a special emphasis on biotechnology as a part of its mission. Furthermore, the fund is currently transitioning to a micro-venture capital model. This will provide startup investment options such as equity, convertible debt, and loan financing options.

## Contacts

5 contacts available for New Orleans BioFund. Shizune tracks 2 team members at New Orleans BioFund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/new-orleans-biofund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 36% |
| Biotechnology | 8 | 36% |
| Medical | 5 | 23% |
| Life Science | 5 | 23% |
| Health Diagnostics | 4 | 18% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 27% |
| Seed | 4 | 18% |
| Venture - Series Unknown | 3 | 14% |
| Series B | 1 | 5% |
| Funding Round | 1 | 5% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Kristopher Khalil | Managing Director | 1 | — |
| Liza Curcio-Rudy | Analyst | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| JuneBrain | JuneBrain is an early start-up company that helps multiple sclerosis patients through the power of telemedicine. It aims to develop a wearable and non-invasive imaging device that enables multiple sclerosis patients to monitor their disease activity at home, leading to earlier detection of MS attacks and improved monitoring of treatment efficacy.Its long-term goal is to extend the use of our device into the broader neurodegenerative disease population, thus creating a pathway towards more frequent, widely accessible monitoring of brain health. |  | Venture - Series Unknown | Apr 03, 2026 |  |
| Altis Biosystems | Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries. The company has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. Their organ on a chip product produces a layer of human or animal intestinal stem anddifferentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening. | $1.4M | Venture - Series Unknown | Aug 02, 2022 |  |
| Obatala Sciences | Obatala Sciences, a fat-on-a-chip biotechnology company, was incorporated to reduce the $2 Trillion economic burden associated with Obesity and Diabetes. Obatala is revolutionizing our view of body fat by highlighting its importance as a functional organ, and a regulator of body health and disease. |  | Series A | Apr 28, 2022 |  |
| Obatala Sciences | Obatala Sciences, a fat-on-a-chip biotechnology company, was incorporated to reduce the $2 Trillion economic burden associated with Obesity and Diabetes. Obatala is revolutionizing our view of body fat by highlighting its importance as a functional organ, and a regulator of body health and disease. |  | Series A | Feb 15, 2022 |  |
| Fluence Analytics | Fluence Analytics is a manufacturer of industrial and laboratory systems that produce continuous data streams. These measurements, combined with powerful, proprietary analytical tools, enable realtime optimization of process control and faster R&D for polymer and biopharmaceutical manufacturers. | $7.5M | Venture - Series Unknown | Aug 16, 2021 |  |
| AxoSim | AxoSim is an operator of a biomimetic neuroscience discovery platform used to develop a 3D cell-based platform that looks and acts like a real nerve. The company empowers advancements in human neuroscience and accelerates the drug development process through its drug discovery platforms, NerveSim and BrainSim.AxoSim was founded in 2014 and isbased in New Orleans, Louisiana. |  | Series A | May 28, 2021 |  |
| 28bio | 28bio is a biotechnology company focused on bridging the gap between human brain biology and drug development using proprietary neurotechnology. Its platform integrates tissue engineering, neural interfacing, and artificial intelligence to build engineered human brain organoids that mimic memory, learning, and other cognitive functions. The goal isto provide more predictive and human-relevant models to improve the success rates of neurological drug discovery, reducing reliance on traditional animal models. | $6.1M | Series A | May 28, 2021 |  |
| Chosen Diagnostics | A biomarker test to diagnose a common and life-threatening bowel disease in preterm infants. It offers more accurate results than current options and allows earlier medical intervention. |  | Convertible Note | Dec 29, 2020 |  |
| BioAesthetics | BioAesthetics was founded in 2015 as a Tulane University spin-out with the mission to improve reconstruction options for breast cancer patients after they undergo mastectomies. The BioAesthetics’ initial product is a tissue-engineered nipple-areolar complex (NAC). This product will be provided to plastic and reconstructive surgeons as anoff-the-shelf ready, acellular, NAC graft. During the breast reconstruction phase, after a mastectomy, the surgeon would engraft the NAC graft in position onto the patient’s reconstructed breast. The patient’s body would then use this NAC graft as a building frame to regenerate their own NAC. This patent-pending product is currently in the pre-clinical phase. | $6.4M | Series A | Oct 05, 2020 |  |
| Altis Biosystems | Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries. The company has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. Their organ on a chip product produces a layer of human or animal intestinal stem anddifferentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening. |  | Seed | May 18, 2020 |  |

10 of 22 investments shown.

## Co-investors
- [SOSV SF & NY (Fka IndieBio)](https://shizune.co/investors/profile/synbio-axlr8r) — VC Fund, 3 deals together
- Tulane Ventures — VC Fund, 3 deals together
- [Energy Innovation Capital](https://shizune.co/investors/profile/energy-innovation-capital) — VC Fund, 2 deals together
- Lagniappe Angels — VC Fund, 2 deals together
- NO/LA Angel Network — VC Fund, 2 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does New Orleans BioFund invest in?

New Orleans BioFund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact New Orleans BioFund?

Public channels for New Orleans BioFund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at New Orleans BioFund?

The team at New Orleans BioFund includes Kristopher Khalil (Managing Director) and Liza Curcio-Rudy (Analyst). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co